Strand Genomics, Inc. (Strand) recently announced its recent unveiling of a full suite of technology solutions that will support its expansion of Strand Centers for Genomics & Personalized Medicine (Strand Centers) into the U.S. At last month’s ACMG 2014 Annual Clinical Genetics Meeting in Nashville, Strand demonstrated how its StrandOmics and Avadis-NGS Server Edition software support the end-to-end clinical genomics services that will be offered by Strand Centers as the company seeks to expand its successful model from India into the United States.
Strand Genomics Announces Availability Of Technology Solutions To Power Expansion Of Personalized Medicine Centers In U.S.
Updated CME Program Is Designed To Help Clinicians Reduce Heart Failure Patient Hospital Readmissions
The SysQuant® study addressing pancreatic cancer published recently in PLOS ONE provides a helicopter view over cell signalling pathways that elegantly demonstrates Proteome Sciences ability to measure the phosphorylation status and expression of very important drug targets and many other signalling proteins. This technology is equally applicable to all cancers. With our collaborators at King’s College Hospital, London SysQuant® identified a number of novel potential therapeutic targets and new diagnostic and prognostic biomarkers covered by patent applications.